If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...
A powerful form of DNA-editing machinery discovered in bacteria might allow us to make much bigger changes to genomes than is currently possible with CRISPR-based techniques. However, it isn’t yet ...
Bring up germline editing, and most scientists cringe. The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos tinkers with DNA far beyond just the patient—any changes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results